Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges

Table 2

Thrombopoietic effect of avatrombopag in liver cancer patients grouped by the status of chronic liver disease.

	Total (n = 93)	CLD (n = 72)	Non-CLD (n = 21)	value^#
Baseline platelet count (×10^9/L)	37.0 (7.0∼49.0)	37.0 (7.0∼49.0)	39.0 (19.0∼49.0)	0.594†
Peak platelet count (×10^9/L)	80.0 (23.0∼357.0)	74.0 (23.0∼328.0)	134.0 (51.0∼357.0)	0.015†
Median increase of platelet count (×10^9/L)	41.0 (2.0∼322.0)	41.0 (2.0∼287.0)	101.0 (23.0∼322.0)	0.020†
Increase of platelet count ≥20 × 10^9/L (P/N)	77/16	56/16	21/0	0.019
Peak platelet count ≥50 × 10^9/L (P/N)	84/9	63/9	21/0	0.201
Peak platelet count ≥50 × 10^9/L and Increase ≥20 × 10^9/L (P/N)	76/17 (81.7%)	55/17 (76.4%)	21/0 (100%)	0.010

Values are median (range); ^# value of the comparison between the CLD and non-CLD groups; †Mann–Whitney U test; Pearson χ.² tests or Fisher’s exact test, as appropriate; abbreviations: CLD: chronic liver disease; P: positive; N: negative.